France· FR:67611486
COPAXONE 40 mg/ml, solution injectable en seringue préremplie
A glatiramer acetate product containing acétate de glatiramère, registered in France by TEVA SANTE, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Glatiramer acetate is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AX13 (glatiramer acetate), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Glatiramer acetate · ATC L03AX13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ACÉTATE DE GLATIRAMÈRE
- Manufacturer
- TEVA SANTE
- Country
- France (FR)
- ATC code
- L03AX13
- ATC class
- Glatiramer acetate
- Defined daily dose
- 20 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093007469512 seringue(s) préremplie(s) en verre de 1 mlEUR 488.31
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for glatiramer acetate.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glatiramer acetate · interactions on record
2 records
- 2 severe
Most severe, free to view
- NatalizumabL04AA23severe
- NatalizumabL04AG03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glatiramer acetate in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsCopaxone 40 mg/ml, oplossing voor injectie in een voorgevulde spuitTeva GmbH
- SwitzerlandCopaxone
- PolandCopaxoneTEVA GmbH
- United KingdomBrabio 20mg/1ml solution for injection pre-filled syringesViatris UK Healthcare Ltd
- IcelandCopaxoneTEVA GmbH
- ItalyCOPAXONETEVA GMBH
- SpainCOPAXONE 20 mg/ml SOLUCION INYECTABLE EN JERINGA PRECARGADATeva Gmbh
- Japanグラチラマー酢酸塩T’sファーマ
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ee99a243-b96b-4fac-8a62-f959260dafd7 GET /v1/drugs/ee99a243-b96b-4fac-8a62-f959260dafd7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67611486",
"date_amm": "2015-11-09",
"type_amm": "Procédure de reconnaissance mutuelle",
"numero_ue": null,
"substance": "ACÉTATE DE GLATIRAMÈRE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about glatiramer acetate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.